Effective with date of service Feb. 28, 2022, the Medicaid and NC Health Choice programs cover cabotegravir extended-release injectable suspension, for intramuscular use (Apretude).
Medicaid Bulletin Monthly Digest
Articles beginning January 2018 are available in the blog format.